Brentuximab vedotin for CD30-positive tumours

Lancet Oncol. 2016 Sep;17(9):e371. doi: 10.1016/S1470-2045(16)30404-1. Epub 2016 Aug 30.

Authors

Shigeo Masuda¹, Shigeru Miyagawa², Terumi Nakamura², Maaz Asher Khurram², Yoshiki Sawa²

Affiliations

¹ Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan. Electronic address: [email protected].
² Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.

PMID: 27599139
DOI: 10.1016/S1470-2045(16)30404-1

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Brentuximab Vedotin
Disease Progression
Disease-Free Survival
Humans
Immunoconjugates / adverse effects
Immunoconjugates / therapeutic use*
Ki-1 Antigen / immunology*
Lymphoma / drug therapy*
Lymphoma / immunology
Lymphoma / mortality
Lymphoma / pathology
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Immunoconjugates
Ki-1 Antigen
Brentuximab Vedotin